Integrin α<sub>v</sub>β<sub>3</sub>-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
Haojun Chen(First Affiliated Hospital of Xiamen University), Liang Zhao(Fujian Medical University), Kaili Fu(Fujian Medical University), Qiuming Lin(Fujian Medical University), Xuejun Wen(Xiamen University), Orit Jacobson(National Institutes of Health), Long Sun(First Affiliated Hospital of Xiamen University), Hua Wu(First Affiliated Hospital of Xiamen University), Xianzhong Zhang(Xiamen University), Zhide Guo(Xiamen University), Qin Lin(Fujian Medical University), Xiaoyuan Chen(National Institutes of Health)
Cited by 105Open Access
Abstract
RATIONALE: Lu as the radionuclide) in the murine colon cancer model. METHODS: Lu TRT was given. RESULTS: T cells, which improved local tumor control, overall survival and protection against tumor rechallenge. Moreover, our data revealed that the time window for this combination therapy may be critical to outcome. CONCLUSIONS: This therapeutic combination may be a promising approach to treating metastatic tumors in which TRT can be used. Clinical translation of the result would suggest that concurrent rather than sequential blockade of the PD-1/PD-L1 axis combined with TRT improves overall survival and long-term tumor control.
Related Papers
No related papers found
Powered by citation graph analysis